Abstract

The airways and alveoli of the human respiratory tract are lined by two distinct types of epithelium, which are the primary targets of respiratory viruses. We previously established long-term expanding human lung epithelial organoids from lung tissues and developed a ‘proximal’ differentiation protocol to generate mucociliary airway organoids. However, a respiratory organoid system with bipotential of the airway and alveolar differentiation remains elusive. Here we defined a ‘distal’ differentiation approach to generate alveolar organoids from the same source for the derivation of airway organoids. The alveolar organoids consisting of type I and type II alveolar epithelial cells (AT1 and AT2, respectively) functionally simulate the alveolar epithelium. AT2 cells maintained in lung organoids serve as progenitor cells from which alveolar organoids derive. Moreover, alveolar organoids sustain a productive SARS-CoV-2 infection, albeit a lower replicative fitness was observed compared to that in airway organoids. We further optimized 2-dimensional (2D) airway organoids. Upon differentiation under a slightly acidic pH, the 2D airway organoids exhibit enhanced viral replication, representing an optimal in vitro correlate of respiratory epithelium for modeling the high infectivity of SARS-CoV-2. Notably, the higher infectivity and replicative fitness of the Omicron variant than an ancestral strain were accurately recapitulated in these optimized airway organoids. In conclusion, we have established a bipotential organoid culture system able to reproducibly expand the entire human respiratory epithelium in vitro for modeling respiratory diseases, including COVID-19.

Details

Title
A bipotential organoid model of respiratory epithelium recapitulates high infectivity of SARS-CoV-2 Omicron variant
Author
Chiu, Man Chun 1   VIAFID ORCID Logo  ; Li, Cun 1 ; Liu, Xiaojuan 1 ; Yu, Yifei 1 ; Huang, Jingjing 1 ; Wan, Zhixin 1 ; Xiao, Ding 1 ; Chu, Hin 2   VIAFID ORCID Logo  ; Cai, Jian-Piao 1 ; Zhou, Biao 3 ; Sit, Ko-Yung 4 ; Au, Wing-Kuk 4 ; Wong, Kenneth Kak-Yuen 4 ; Li, Gang 5 ; Chan, Jasper Fuk-Woo 6   VIAFID ORCID Logo  ; To, Kelvin Kai-Wang 6   VIAFID ORCID Logo  ; Chen, Zhiwei 7   VIAFID ORCID Logo  ; Jiang, Shibo 8   VIAFID ORCID Logo  ; Clevers, Hans 9   VIAFID ORCID Logo  ; Yuen, Kwok Yung 6   VIAFID ORCID Logo  ; Zhou, Jie 2   VIAFID ORCID Logo 

 The University of Hong Kong, Pokfulam, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757) 
 The University of Hong Kong, Pokfulam, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); The University of Hong Kong, State Key Laboratory of Emerging Infectious Diseases, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong, China (GRID:grid.194645.b) 
 The University of Hong Kong, AIDS Institute, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757) 
 The University of Hong Kong, and Queen Mary Hospital, Department of Surgery, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757) 
 Southern Medical University, Department of Otolaryngology-Head and Neck Surgery, Precision Medicine Center, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) 
 The University of Hong Kong, Pokfulam, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); The University of Hong Kong, State Key Laboratory of Emerging Infectious Diseases, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong, China (GRID:grid.194645.b); Carol Yu Centre for Infection, The University of Hong Kong, Pokfulam, China (GRID:grid.194645.b) (ISNI:0000000121742757) 
 The University of Hong Kong, Pokfulam, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); The University of Hong Kong, State Key Laboratory of Emerging Infectious Diseases, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757); The University of Hong Kong, AIDS Institute, Li Ka Shing Faculty of Medicine, Hong Kong, China (GRID:grid.194645.b) (ISNI:0000000121742757) 
 Fudan University, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443) 
 Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), and University Medical Center (UMC) Utrecht, Utrecht, the Netherlands (GRID:grid.419927.0) (ISNI:0000 0000 9471 3191) 
Publication year
2022
Publication date
2022
Publisher
Springer Nature B.V.
e-ISSN
20565968
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2677214147
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.